Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.85
-0.19 (-2.70%)
Nov 4, 2024, 4:00 PM EST - Market closed
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2023. The number of employees increased by 2 or 33.33% compared to the previous year.
Employees
8
Change (1Y)
2
Growth (1Y)
33.33%
Revenue / Employee
$1,194,289
Profits / Employee
-$1,262,449
Market Cap
104.27M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | 2 | 33.33% |
Dec 31, 2022 | 6 | 0 | - |
Dec 31, 2021 | 6 | - | - |
Related Stocks
Company Name | Employees |
---|---|
EDAP TMS | 307 |
Century Therapeutics | 165 |
Immunic | 77 |
Assembly Biosciences | 65 |
Werewolf Therapeutics | 47 |
Sensus Healthcare | 35 |
Relmada Therapeutics | 20 |
Regencell Bioscience Holdings | 12 |
COYA News
- 3 days ago - Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer - Business Wire
- 4 days ago - Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off - Seeking Alpha
- 6 days ago - Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Benzinga
- 6 days ago - Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial - Reuters
- 6 days ago - Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain) - Business Wire
- 7 days ago - Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease - Business Wire
- 12 days ago - Coya Therapeutics Announces Closing of $10.0 Million Private Placement - Business Wire
- 13 days ago - Coya Therapeutics Announces $10.0 Million Private Placement - Business Wire